



US government (USG) investment in global health R&D has delivered

\$26.4 million
to Arizona research institutions*

350+ new jobs
for Arizona†

Arizona's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
University of Arizona	\$13.6 million
Arizona State University	\$11.8 million
The Translational Genomics Research Institute	\$951 thousand

Global health R&D at work in the Grand Canyon State



Arizona State University researchers have developed a technology to turn smartphones into a low-cost microscope to detect tuberculosis and other infectious diseases. The team took an expensive technology called dark-field microscopy, which allows scientists to more clearly see brightly lit samples against a black background, and adapted it for low-resource settings. They created an easy-to-use mobile phone attachment that combines a \$1 LED light with a condenser to help focus light onto a sample. The tool also contains a slide reader and slides customized to detect a specific disease and its severity. This simple, portable technology could be a valuable new tool for health workers on the front lines of triaging outbreaks around the world.


Neglected diseases in Arizona‡

HIV diagnoses	6,054
Tuberculosis cases	1,970
West Nile cases	739
Malaria cases	157
Dengue cases	150

Arizona industry in global health R&D

BCR Diagnostics: Chandler
Celgene: Phoenix
Yaso Therapeutics: Phoenix

Arizona's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡

89¢ of every dollar
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, West Nile virus disease cases 2008-2016, Malaria cases 2008-2014, Dengue virus infection cases 2010-2016.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.